“The regulatory perspective: benefits and limits of 3D printed drugs” – Presented by Dr. William Shang, Johnson & Johnson

Dr. William Shang

“The regulatory perspective: benefits and limits of 3D printed drugs” – Presented by Dr. William Shang, Johnson & Johnson. 3DP technology is already up and running in many areas. The future definitely looks promising when considering the idea of 3DPs, but are the regulatory agencies ready for such technology? The presentation will reflect the regulators views and concerns about pharmaceutical development, manufacturing and control of this new technology. Potential clinical and preclinical obstacles in terms of practical use will be addressed as well.

About Dr. William Shang Continue reading ““The regulatory perspective: benefits and limits of 3D printed drugs” – Presented by Dr. William Shang, Johnson & Johnson”